There is a dire need for a vaccine for COVID-19 (SARS-CoV-2 disease) because of the number of cases worldwide. The vaccine now is the most efficient way to contain the spread of COVID-19 and prevent its future onset. However, there exist pertinent technological hitches in designing and developing a vaccine for COVID-19. CRISPR-mediated genome editing approach has been developed for repurposing into a cell-modification endeavor in addition to correcting defective parts of the genome. Creative Biolabs provides the B cell engineering service to manufacture antibodies to defend against the invasion of COVID-19 virus.
B cells play a very important role in the adaptive immune response. It helps control, destroy, and remove viruses or bacteria. When the SARS-CoV-2 virus arrives, naïve B cells are activated with the help of follicular T (TFH) cells. After their interaction of them, B cells proliferate and differentiate rapidly, producing pre-germinal center memory B cells (pre-GC MBCs) and short-lived plasma cells (SLPCs), and producing low-affinity early antibodies. In addition, other B cells enter the germinal center (GC), and grow long-lived plasma cells (LLPCs) and memory B cells (MBCs). When the second invasion or vaccination arrives, both the pre-GC MBC and the MBC produced after the GC reaction differentiates into plasma cells, resulting in high-affinity antibodies. These secreted antibodies enter the blood circulation and peripheral tissues to defend against viral infections and reinfection.
Fig.1 The role of B cells in COVID-19 infection and re-infection. (Chen, et al., 2022)
With this premise, B cells can be modified into antigen-specific, permanently viable, non-carcinogenic, relatively benign antibody-producing cells that can be used as effective vaccines for COVID-19. Similarly, this method can be applied to other viruses or pathogens. In detail, genome editing-based methods are modified to replace endogenously encoded antibodies with antibodies to specific antigens (COVID-19) in B cells.
Fig.2 B cell engineering service for anti-COVID-19 antibody delivery. (Creative Biolabs)
For more B cell engineering information, please visit the unit of Engineering Cancer Cells for Self-destruction. If you have interest, please do not hesitate to contact us.
|
|
B Cell Engineering Service for Anti-HIV Antibody Delivery |
| Creative Biolabs provides the B cell engineering service to manufacture antibodies to defend against the invasion of HIV virus. Please click to know more. | |
|
|
B Cell Engineering Service for Anti-RSV Antibody Delivery |
| Creative Biolabs provides B cell engineering services by different genome editing methods to manufacture antibodies to defend against the invasion of RSV. Please click to know more. | |
|
|
B Cell Engineering Service for Anti-Influenza Virus Antibody Delivery |
| Creative Biolabs provides the B cell engineering service to manufacture antibodies to defend against the invasion of the influenza virus. Please click to know more. | |
|
|
B Cell Engineering Service for Anti-EBV Antibody Delivery |
| Creative Biolabs provides B cell engineering services to manufacture antibody by to defend against the invasion of EVB. Please click to know more. |
Q2. How to make sure that the engineered B cell is not oncogenic?
A: 1. Repeated culture of B cells can be done and various assays performed to know if the strain is safe for the recipient.
2. A set of assays and tests can be developed to create a worksheet and protocol to ensure the selection of viable and safe engineered B cells.
